Kazia Therapeutics directors demonstrate confidence in bio-tech strategy with on-market purchases Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) directors have demonstrated confidence in the companys bio-tech strategy with on-market share purchases. Non-executive director Steven Coffey acquired 8,000 shares in an indirect interest on June 1 and 2, increasing his holding to 426,250 shares with another 8,015 held in a direct interest. On May 31 executive director and CEO Dr James Garner purchased 10,000 shares in a direct interest, increasing the number of securities held to 430,000. Non-executive director Bryce Carmine acquired 20,000 shares on May 31 in a direct interest, increasing his holding to 372,692 shares. This follows multiple purchases made by KZA directors on May 3. March quarter highlights The company kicked off 2021 with a trifecta of March quarter licensing deals, leaving it "a vastly stronger and more substantial business", according to CEO Dr James Garner. During the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million by the end of March.